
MONOCLONAL ANTIBODIES



Immune Response


Polyclonal Ab (Derived form different Plasma cells)





Monoclonal Ab

Specific to single epitope (Derived form single Plasma cell)



HYBRIDOMA TECHONOLOGY

- ✓ Normal cells are fused with a cancerous cell line
 - E.g. Myeloma
- Fusion is accomplished with PEG (polyethylene glycol)
- ✓ The new hybrid cell exhibits properties of both cell types

- Unlimited growth
- Secretes monoclonal antibody
 - Or secretes cytokines







Figure 4-25
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

- > For monoclonal antibody production
- 1. Animal is immunized with antigen
- 2 Spleen cells are isolated
- Fused with myeloma cells using PEG
- This cell is deficient in HGPRT (hypoxantine guanine phosphoribosyl transferase)
- Alternatively TK (thymidine kinase deficient)
- > Fails to survive in selection medium
- Aminopterin inhibits "De novo Pathway", "Salvage Pathway" is not possible due to HGPRT or TK deficiency
- Also Ig Deficient
- 1/- It can not secret any immunoglobulins








The types of mAb designed

- A. Murine source mAbs: rodent mAbs with excellent affinities and specificities, generated using conventional hybridoma technology. Clinical efficacy compromised by HAMA(human anti murine antibody) response, which lead to allergic or immune complex hypersensitivities.
- 2. B. Chimeric mAbs: chimers combine the human constant regions with the intact rodent variable regions. Affinity and specificity unchanged. Also cause human anti chimeric antibody response (30% murine resource)
- C. Humanized mAbs: contained only the CDRs of the rodent variable region grafted onto human variable region framework


Evolution of Therapeutic Antibodies

Evolution of Therapeutic Antibodies




APPLICATION OF MONOCLONAL ANTIBODIÉS

- Diagnostics
- Immunotoxin




ANTIGEN ANTIBODY INTERACTION



Important terms:

- Affinity- The combined strength of the non covalent interactions between a
 single antigen-binding site on an antibody and a single epitope.
- 2. Avidity-The strength of such multiple interactions between a multivalent antibody and antigen
- Cross reactivity- antibody elicited by one antigen can cross-react with an unrelated antigen




- 1. The association between a binding site on an antibody (Ab) with a monovalent antigen (Ag) can be described by the equation:
- 2. Ag + Ab ----- Ag-Ab
- з. Ka, equilibrium constant for association: Ka = [Ag-Ab] / [Ab][Ag]
- 4. Low-affinity Ag-Ab complexes have Ka values between 10 and 10 L/mol: high-affinity complexes can have Ka values as high as 10 L/mol.
- 5. The equilibrium constant for dissociation reaction is Kd, the reciprocal of Ka


$$Kd=[Ab][Ag]/[Ab-Ag] = 1/K$$

A quantitative indicator of the stability of an Ag-Ab complex

Ka, can be determined by equilibrium dialysis




Scatchard equation: r/c = Kan -Kar



Precipitation reaction


- Precipitation in fluids
- Bivalent Ab
- Bivalent/ Multivalent Ag




RADIAL IMMUNODIFFUSION


- A quantitative technique based upon the reaction between an Ag placed in a well diffuses into an agar containing the Ab.
- During diffusion period the Ag & Ab continue to react until the zone of equivalence is reached with formation of a well-defined ring of precipitation around the Ag well which

is proportional to the Ag concentration.









<u>Immunoelectrophoresis</u>


- Qualitative technique
- Antigen mixture is first electrophoresed



 Antiserum is added to the troughs which are parallel to the direction of the electric field



Antibody and antigen then diffuse toward each other and produce lines of precipitation where they meet in appropriate proportions



THANKS